School of Chemistry and Life Sciences, Hubei University of Education, Wuhan, Hubei, 430205, PR China.
Hubei Key Laboratory of Purification and Application of Plant Anticancer Active Ingredients, School of Chemistry and Life Sciences, Hubei University of Education, Wuhan, Hubei, 430205, PR China.
Hypertens Res. 2024 Feb;47(2):375-384. doi: 10.1038/s41440-023-01460-2. Epub 2023 Oct 23.
The SARS-CoV-2 pandemic, now in its third year, has had a profound impact on public health and economics all over the world. Different populations showed varied susceptibility to this virus and mortality after infection. Clinical and laboratory data revealed that the uncontrolled inflammatory response plays an important role in their poor outcome. Herein, we summarized the role of NF-κB activation during SARS-CoV-2 invasion and replication, particularly the angiotensin-converting enzyme 2 (ACE2)-mediated NF-κB activation. Then we summarized the COVID-19 drugs' impact on NF-κB activation and their problems. A favorable prognosis is linked with timely treatment with NF-κB activation inhibitors, such as TNFα, IL-1β, and IL-6 monoclonal antibodies. However, further clinical researches are still required to clarify the time window, dosage of administration, contraindication, and potential side effects of these drugs, particularly for COVID-19 patients with hypertension, hyperglycemia, diabetes, or other chronic diseases.
SARS-CoV-2 大流行已进入第三个年头，对全球公共卫生和经济造成了深远影响。不同人群对这种病毒的易感性和感染后的死亡率存在差异。临床和实验室数据表明，失控的炎症反应在其不良预后中起着重要作用。在此，我们总结了 NF-κB 激活在 SARS-CoV-2 入侵和复制过程中的作用，特别是 ACE2 介导的 NF-κB 激活。然后，我们总结了 COVID-19 药物对 NF-κB 激活的影响及其存在的问题。及时使用 NF-κB 激活抑制剂（如 TNFα、IL-1β 和 IL-6 单克隆抗体）治疗与良好的预后相关。然而，仍需要进一步的临床研究来阐明这些药物的时间窗、给药剂量、禁忌证和潜在副作用，特别是对于患有高血压、高血糖、糖尿病或其他慢性疾病的 COVID-19 患者。
